| Literature DB >> 33572615 |
Hengju Ge1, Di Zhang1,2, Muran Shi3, Xiaoyuan Lian3, Zhizhen Zhang1.
Abstract
In 2019, streptoglutarimide H (SGH) was characterized as a new glutarimide from the secondary metabolites produced by a marine-derived actinomycete Streptomyces sp. ZZ741 and shown to have in vitro antiglioma activity. However, the antiproliferative activity and potential mechanism of SGH against lung cancer cells have not yet been characterized. This study demonstrated that SGH significantly inhibited the proliferation of different lung cancer cells. In terms of mechanism of action, SGH downregulated cell cycle- and nucleotide synthesis-related proteins to block cell cycle at G0/G1 phase, reduced the expression levels of glycolytic metabolic enzymes to inhibit glycolysis, and downregulated the important cancer transcription factor c-Myc and the therapeutic target deubiquitinase USP28. Potent anticancer activity and multiple mechanisms indicated SGH to be a novel antitumor compound against lung cancer cells.Entities:
Keywords: Streptoglutarimide H; USP28; antiproliferative activity; c-Myc; cell cycle block; glycolysis; lung cancer cells
Mesh:
Substances:
Year: 2021 PMID: 33572615 PMCID: PMC7911229 DOI: 10.3390/md19020079
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118